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Ingelheim, Germany; 6Tufts University School of Medicine, Boston, MA, USAA B S T R A C TObjectives: To critically appraise published network meta-analyses
(NMAs) evaluating the efﬁcacy or safety of the new oral anticogulants
(NOACs) dabigatran, rivaroxaban, and apixaban for the prevention of
stroke in patients with nonvalvular atrial ﬁbrillation (AF). Methods: A
systematic literature review was performed to identify the relevant
NMAs using MEDLINE, EMBASE, Cochrane Library, Database of Abstracts
of Reviews of Effects, and Health Technology Assessment. The syn-
thesis studies were evaluated using the “Questionnaire to assess the
relevance and credibility of the NMA.” Results: Eleven NMAs evaluating
NOACs among adults with nonvalvular AF were identiﬁed. Most NMAs
included three large phase III randomized controlled trials, comparing
NOACs to adjusted-dose warfarin (Randomized Evaluation of Long-
Term Anticoagulation Therapy [RE-LY], Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-
AF], and Apixaban for Reduction of Stroke and Other Thromboembolic
Events in Atrial Fibrillation [ARISTOTLE]). The main differences identi-
ﬁed related to potential treatment effect modiﬁers regarding the mean
time spent in therapeutic range (TTR) in the warfarin arm, the risk of
stroke or systemic embolism across the trials (mean CHADS2 score: C ¼
congestive heart failure, H ¼ hypertension, A ¼ older than age 75 years,ee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.10.012
apigroup.com.
ndence to: Shannon Cope, 33 Bloor Street East, SuD ¼ diabetes mellitus, S2 ¼ prior stroke or history of transient ischemic
attack) or primary versus secondary prevention, and type of populations
used in the analysis. Kansal et al. [Kansal AR, Sharma M, Bradley-
Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of
stroke and systemic embolism in atrial ﬁbrillation in Canada: compa-
rative efﬁcacy and cost-effectiveness. Thromb Haemost 2012;108:672–
82] appropriately adjusted the ROCKET-AF TTR to match the RE-LY
population on the basis of individual patient data. Meta-regressions are
not expected to minimize confounding bias given limited data, whereas
subgroup analyses had some impact on the point estimates for the
treatment comparisons. Conclusions: Results of the synthesis studies
were generally comparable and suggested that the NOACs had similar
efﬁcacy, although some differences were identiﬁed depending on the
outcome. The extent to which differences in the distribution of TTR,
CHADS2 score, or primary versus secondary prevention biased the
results remains unclear.
Keywords: atrial ﬁbrillation, network meta-analysis, new oral
anticoagulant, systematic review.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Atrial ﬁbrillation (AF) is the most common chronic cardiac rhythm
abnormality. The worldwide prevalence of AF is 1% to 2% overall
[1], but it increases with age to up to 17.8% among those 85 years
or older [2]. AF is associated with a ﬁvefold increase in the risk of a
stroke [3] and leads to a 30-day stroke mortality of 24% in the
absence of treatment [4]. Patients with AF who experience a stroke
are at a higher risk of mortality, morbidity, disability, and longer
hospital stays than are patients with stroke without AF [5].Stroke prevention is the main goal for managing patients with
AF. The vitamin K antagonist warfarin has long been the main-
stay of treatment to prevent stroke in patients with AF [6,7].
However, it is associated with bleeding complications, as well as
several food and drug interactions, and therefore requires coag-
ulation monitoring for dose adjustments to maximize the
amount of time spent in therapeutic range (TTR) of international
normalized ratio (2–3) [8–12]. These limitations have restricted
the use of warfarin [13] and have led to the development of new
oral anticoagulants (NOACs), which provide predictableociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ite 1300, Toronto, ON, Canada M4W 3H1.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 3 4 – 2 4 9 235anticoagulation using a ﬁxed-dose administration, thereby elim-
inating the need for routine monitoring.
Dabigatran etexilate (dabigatran), a reversible direct thrombin
inhibitor, was the ﬁrst NOAC approved on the basis of a landmark
study in 2009 (Randomized Evaluation of Long-Term Anticoagu-
lation Therapy [RE-LY] [14,15]). Two additional large randomized
controlled trials (RCTs) assessing the orally administered directly
activated coagulation factor Xa inhibitors rivaroxaban and apix-
aban were recently published (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared With Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibrillation
[ROCKET-AF] [16] and Apixaban for Reduction of Stroke and Other
Thromboembolic Events in Atrial Fibrillation [ARISTOTLE] [17]).
These trials demonstrated that each NOAC was noninferior or
superior to warfarin for the prevention of stroke among patients
with nonvalvular AF and was comparable or more favorable in
terms of major bleeding complications, which led to the approval
of these drugs in the United States and Europe.
For decision makers to assess the comparative efﬁcacy and
safety of the alternative NOACs in the absence of a head-to-head
RCT comparing these treatments, an indirect treatment compar-
ison or network meta-analysis (NMA) using warfarin as a com-
mon comparator can be performed. NMA is an extension of
pairwise meta-analysis and includes multiple different pairwise
comparisons assessed in RCTs, in which each RCT has at least
one intervention in common with another trial [18–21]. Health
technology assessment agencies are increasingly using these
methods [22–25]. Despite the limited number of phase III RCTs
evaluating NOACs for stroke prevention among patients with AF,
numerous (network) meta-analyses have been published. Given
the increasing number of NMAs [26], it is increasingly important
to assess whether synthesis studies provide a fair reﬂection of
the existing evidence base, whether they include reasonable and
adequately justiﬁed assumptions, and whether they are a rea-
sonable basis for decision making [27]. Therefore, the aim of this
study was to critically appraise the published NMAs evaluating
the efﬁcacy or safety of the NOACs dabigatran, rivaroxaban, and
apixaban for the prevention of stroke in patients with non-
valvular AF, using a questionnaire to assess the relevance and
validity of NMAs recently developed by the International Society
of Pharmacoeconomics and Outcomes Research (ISPOR) [28].Methods
Identiﬁcation and Study Selection
A systematic literature search of MEDLINE, MEDLINE In-Process,
and EMBASE databases from inception to November 2012 (see
Search strategy in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.10.012 for search terms) was performed.
The Cochrane Library, the Database of Abstracts of Reviews of
Effects, and the Health Technology Assessment publications were
also searched using a simpliﬁed strategy. The relevance of each
citation identiﬁed was based on title and abstract (or full-text
article) according to the following selection criteria predeﬁned in a
protocol:1. Population: Adults aged 18 years and older with nonvalvular AF.
2. Interventions: NOACs, including dabigatran, rivaroxaban, and
apixaban.
3. Comparators: NOACs, warfarin, anticoagulants, antiplatelets,
direct thrombin inhibitors and factor Xa inhibitors, or placebo.
4. Outcomes: Stroke or systemic embolism (SE), myocardial
infarction (MI), overall mortality, cardiovascular (CV) death,
major hemorrhage, and intracranial hemorrhage.5. Study design: NMA of RCTs.Full-text publications in English, French, and German were
obtained and reference lists were hand searched. The NMAs included
in the systematic review will be referred to as “synthesis studies.”
Data Extraction of Synthesis Studies
For each synthesis study, details were extracted regarding the
research question, method of review and synthesis, method to
identify and evaluate potential treatment effect modiﬁers, results
and conclusions for outcomes of interest, and conﬂicts of
interest.
Critical Appraisal of Synthesis Studies
Each synthesis study was critically appraised using the “Question-
naire to assess the relevance and credibility of a network meta-
analysis” [28]. Questionnaire items related to the relevance of the
studies or the usefulness of the NMA to inform health care decision
making were not scored but can be assessed by each decision
maker on the basis of information summarized. The questionnaire
items related to the validity of the analysis were scored with yes/
no/not reported and discussed in a narrative summary.Results
Identiﬁcation and Study Selection
The database search identiﬁed 833 records, and a hand search
identiﬁed an additional 10 records [29–38] (Appendix Figure 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.10.012 illustrates the selection process). Meta-analyses were
not of interest, even if considering NOACs of interest as a class
versus warfarin [29,32,33,35,39–41], because decision makers are
faced with a choice regarding the individual NOACs and differ-
ences between NOACs in terms of the mode of action, pharma-
cology, pharmacokinetics, and drug interactions suggest that
they should be regarded as distinct treatments [42]. Eleven syn-
thesis studies were identiﬁed that combined RCTs using an NMA
evaluating one or more of the NOACs of interest among adults
with nonvalvular AF [31,34,36,43–50]. The Evidence Review Group
report by Spackman et al. [37] related to the publication by
Roskell et al. [48], which was used as the primary source.
Summary of the Synthesis Studies
All synthesis studies were based on RCTs that included adults with
nonvalvular AF and evaluated dabigatran (n ¼ 11), rivaroxaban (n¼
10), and apixaban (n ¼ 8) against adjusted-dose warfarin. Both
doses of dabigatran (dabigatran 110 mg and dabigatran 150 mg)
were included in the synthesis studies with the exception of
Edwards et al. [34], which excluded dabigatran 110 mg. Two
synthesis studies also included ximelagatran (Edwards et al. [34]
and Roskell et al. [48]), which reﬂects an NOAC that is no longer
approved because of safety concerns and therefore is not relevant
for the decision problem. Appendix Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.012 sum-
marizes the outcomes assessed, which included overall mortality,
stroke or SE, and MI most commonly. A summary of the ques-
tionnaire items is presented in Table 1, and the main differences
and similarities are discussed in the following sections.
Evidence Base Used in the Synthesis Studies
Methods used by the synthesis studies to identify and select
RCTs
A systematic literature review to identify the relevant RCTs was
performed by all synthesis studies except for four studies
Table 1 – Overview of network meta-analyses questions regarding credibility (no. 5–23).
ISPOR criteria Baker et al.
[43]
Wells et al.
[31]
Edwards
et al.
[34]
Harenberg
et al. [44]
Kansal
et al. [45]
Lip et al.
[46]
Mantha
and Ansell
[47]
Rasmussen
et al. [36]
Roskell
et al. [48]
Schneeweiss
et al. [49]
Testa et al.
[50]
1. Did the researchers
attempt to identify
and include all
relevant
randomized
controlled trials
(RCTs)?
✓ (SLR
multiple
databases)
✓ (SLR
multiple
databases)
x (no SLR) ✓ (SLR
multiple
databases,
excluded if
not ALL
end points
included)
x (no SLR) x (no SLR) ✓ (SLR
PubMed
only)
✓ (SLR
multiple
databases)
✓ (SLR
multiple
databases)
✓ (SLR
multiple
databases)
✓ (SLR
multiple
databases)
2. Do trials for
interventions of
interest form one
connected network
of RCTs?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3. Is it apparent that
poor quality
studies were
included, thereby
leading to bias?
N (rated as
“good”
except
PETRO
rated as
“fair”)
N (all “good”
or “very
good”)
? (no QA) ? (no QA) ? (no QA) ? (no QA) ? (no QA) ? (no QA) N (restricted
analyses
to studies
with Jadad
scores of
42)
? (no QA) N (all studies
low risk of
bias)
4. Is it likely that bias
was induced by
selective reporting
of outcomes in the
studies?
? N ? ? ? ? ? ? ? ? ?
5. Are there
systematic
differences in
treatment effect
modiﬁers across
the different
treatment
comparisons in the
network?
N Y N Y Y Y N Y Y Y N
6. Were imbalances
in effect modiﬁers
across the
different
treatment
comparisons
identiﬁed before
reviewing
individual study
results?
✓ ✓ x ✓ ✓ ✓ ✓ ✓ ✓ ✓ x
7. Were statistical
methods used that
preserve within-
study
randomization?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
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8. If both direct and
indirect
comparisons are
available for
pairwise contrasts,
was agreement
evaluated or
discussed?
NA (ITC) ✓ NA (ITC) NA (closed
loop in
one study
only)
NA (ITC) NA (ITC) NA (ITC) NA (closed
loop based
on one
study
only)
x NA (ITC) NA (ITC)
9. In the presence of
consistency, were
both direct and
indirect evidence
included in the
network meta-
analysis?
NA NA NA NA NA NA NA NA ✓ NA NA
10. With an
imbalance in the
distribution of
treatment effect
modiﬁers across
the different types
of comparisons in
the network of
trials, did
researchers
attempt to
minimize this bias
with the analysis?
✓ (tested
meta-
regression
TTR and
CHADS2)
✓ (subgroup
analyses
for age,
CHADS2,
TTR)
x x ✓ (TTR
adjus-
ted;
assessed
ITT and
SOT)
x x ✓ (subgroups
for
previous
stroke Y/
N)
✓ (duration
of follow-
up
covariate;
analysis
including
only
studies
with INR
2.0–3.0)
✓ (subgroup
CHADS2
score Z 3)
x
11. Was a valid
rationale provided
for the use of RE or
FE models?
x ✓ ✓ x x ✓ x x x x ✓
12. If a RE model was
used, were
assumptions about
heterogeneity
explored or
discussed?
✓ ✓ ✓ NA (FE
model)
NA (FE
model)
NA (FE
model)
NA (FE
model)
NA (FE
model)
✓ NA (FE model) ✓
13. Is a graphical or
tabular
representation of
the evidence
network provided
with information
on the number of
RCTs per direct
comparison?
x ✓ ✓ ✓ x x ✓ x ✓ ✓ x
14. Are the individual
study results
reported?
✓ ✓ (except
D110 vs.
D150)
x (only
ROC-
KET-AF
results)
✓ ✓ ✓ ✓ x ✓ ✓ ✓
15. Are direct results
reported
separately from
x ✓ ✓ Only one RCT
per
contrast
Only one
RCT per
contrast
Only one
RCT per
contrast
Only one
RCT per
contrast
x x Only one RCT
per contrast
Only one RCT
per
contrast
continued on next page
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Table 1 – continued
ISPOR criteria Baker et al.
[43]
Wells et al.
[31]
Edwards
et al.
[34]
Harenberg
et al. [44]
Kansal
et al. [45]
Lip et al.
[46]
Mantha
and Ansell
[47]
Rasmussen
et al. [36]
Roskell
et al. [48]
Schneeweiss
et al. [49]
Testa et al.
[50]
results of indirect
comparisons or
network meta-
analyses?
16. Are all pairwise
contrasts between
interventions as
obtained with
NMA reported
along with
measure of
uncertainty?
✓ ✓ x ✓ ✓ ✓ ✓ ✓ x ✓ ✓
17. Is a ranking of
interventions
provided given the
reported treatment
effects and its
uncertainty by
outcome?
NA ✓ x NA NA NA NA NA NA NA NA
18. Is the impact of
important patient
characteristics on
treatment effects
reported?
✓ ✓ x x ✓ x x ✓ N ✓ N
Note. Questions 1 to 4 regarding relevance are described qualitatively in the main body of the results.
CHADS2, Cardiac failure, Hypertension, Age Z 75 years, Diabetes mellitus, Stroke; D110, dabigatran 110 mg; D150, dabigatran 150 mg; FE, ﬁxed effect; INR, international normalized ratio; ISPOR,
International Society of Pharmacoeconomics and Outcomes Research; ITC, indirect treatment comparison; ITT, intention to treat; N, no; NA, not applicable; NMA, network meta-analysis; NR,
not reported; PETRO, study, Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation; QA, quality assessment; RCT,
randomized controlled trial; SLR, systematic literature review; SOT, safety on treatment; TTR, time spent in therapeutic range; Y, yes.
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Dabigatran
110 mg BID 
Rivaroxaban
20 mg OD
RE-LY 2009 (11/11)
PETRO 2007 (2/11)
ROCKET-AF 2011 (10/11)ARISTOTLE 2011 (8/11)
Dabigatran
150 mg BID 
Apixaban
5 mg BID
Adjusted-dose 
warfarin
Ximelagatran
36 mg BID
SPORTIF III 2003 (2/11)
SPORTIF V 2005 (2/11)
RE-LY 2009 (10/11)
RE-LY 2009 (3/11)
Fig. 1 – Network of RCTs included in the synthesis studies. The number of synthesis studies that included each RCT per
treatment comparison is presented out of the 11 included synthesis studies. Note. Additional treatments included in the
networks for Roskell et al. [48] and Edwards et al. [34] beyond warfarin and NOACs were excluded from this ﬁgure.
ARISTOTLE, Apixaban for Reduction of Stroke and Other Thromboembolic Events in Atrial Fibrillation; BID, twice daily; OD,
once daily; RCT, randomized controlled trial; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET-
AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation; SPORTIF, stroke prevention with the oral direct thrombin inhibitor ximelgatran
compared with warfarin in patients with non-valvular atrial ﬁbrillation.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 3 4 – 2 4 9 239[34,36,45,46]. Despite differences in the methodology to identify
the RCTs, which are summarized in Appendix Table 2 in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.
012, the synthesis studies focused on the large pivotal RCTs for
the NOACs of interest. Figure 1 presents the network of RCTs
included in the synthesis studies, which focused on the phase III
studies RE-LY, ROCKET-AF, and ARISTOTLE. These trials included
18,113, 14,264, and 18,201 patients, respectively, and had a
median follow-up period ranging between 1.8 and 2 years. The
inclusion criteria were consistently based on the deﬁnition of
nonvalvular AF and additional risk factors based on the CHADS2
score. CHADS2 is a validated risk score to predict the risk of
stroke in patients with AF [31] and relates to congestive heart
failure (C), hypertension (H), older than age 75 years (A),
diabetes mellitus (D), prior stroke or history of transient ische-
mic attack (S2). It should be noted that in RE-LY patients were
also included if they were between 65 and 74 years old and had
diabetes mellitus, hypertension, or coronary artery disease.
Phase II RCTS [51,52], a recent phase III Japanese study (Japa-
nese-ROCKET [53]), and a study comparing apixaban to aspirin
(Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial
Fibrillation patients Who Have Failed or Are Unsuitable for
Vitamin K Antagonist Treatment [AVERROES] [54]) were not
generally included.Quality assessment performed by the synthesis studies
Several synthesis studies did not report a quality assessment of
the RCTs [34,36,44–46,49] and those that did used different
instruments [55–58]. The main differences in the trials related
to the blinding and study population analyzed in the trials (i.e.,
intention to treat [ITT] or safety on treatment [SOT]). Although
ROCKET-AF and ARISTOTLE were double-blind trials, a prospec-
tive randomized open blinded end-point design was used for RE-
LY, in which patients and investigators were blinded only to thetwo dabigatran doses, whereas end-point assessors were blinded
during central event adjudication and analyses. Information
regarding selective reporting of outcomes was reported only by
Wells et al. [31], suggesting that this was not a major threat to the
validity.
Statistical Analysis Performed in the Synthesis Studies
Type of evidence synthesis
Importantly, all studies used statistical methods that synthesized
results of RCTs acknowledging within-trial randomization (i.e.,
no “naive” comparisons were performed) [28]. Table 2 provides an
overview of the included RCTs and analysis methods of each
synthesis study. The most common analysis was a frequentist-
adjusted indirect treatment comparison using warfarin as the
common comparator, based on the Bucher method [36,43,45–
47,49,50]. Three analyses could be considered as mixed treatment
comparisons [31,44,48] because they included a “closed loop” in
the network between dabigatran 110 mg, dabigatran 150 mg, and
warfarin. Because these estimates were based on only one trial
(RE-LY), they will be consistent with each other by deﬁnition and
the mixed treatment comparisons are not expected to differ from
the indirect treatment comparisons. Consequently, inconsisten-
cies in the direct and indirect evidence are not a threat to the
validity of the analyses and therefore will be referred to as
“NMAs.” An advantage of synthesis studies using a Bayesian
approach is that the method naturally leads into a decision
framework to support decision making and allows for the
estimation of rank probabilities [21].
Fixed or random effects approach
All the NMAs used a ﬁxed effect model as the base case analysis,
given the limited number of trials. Select synthesis studies also
used a random effects model [31,34,48], and these studies tended to
Table 2 – Overview of network meta-analyses performed and RCTs included per treatment comparison.
Study Analysis Model Outcome D150 vs. W D110
vs. W
R vs. W A vs. W D150 vs.
D110
X vs. W Other
Wells et al. [31] Bayesian/frequentist MTC FE/RE OR RE-LY RE-LY ROCKET-AF ARISTOTLE RE-LY NA NA
Harenberg et al. [44] Frequentist MTC FE OR RE-LY RE-LY ROCKET-AF ARISTOTLE RE-LY NA NA
Lip et al. [46] Frequentist ITC (Bucher) FE HR RE-LY RE-LY ROCKET-AF ARISTOTLE NA NA NA
Rasmussen et al. [36] Frequentist ITC (Bucher) FE HR RE-LY RE-LY ROCKET-AF ARISTOTLE NA NA NA
Testa et al. [50] Frequentist ITC (Bucher) FE OR RE-LY RE-LY ROCKET-AF ARISTOTLE NA NA NA
Baker et al. [43] Frequentist ITC (Bucher) FE Risk ratio RE-LY PETRO RE-LY ROCKET-AF ARISTOTLE NA NA NA
Mantha and Ansell [47] Frequentist ITC (Bucher) FE OR RE-LY RE-LY ROCKET-AF ARISTOTLE NA NA NA
Schnee-weiss et al. [49] Frequentist ITC (Bucher) FE HR RE-LY RE-LY ROCKET-AF ARISTOTLE NA NA NA
Kansal et al. [45] Frequentist ITC (Bucher) FE RR RE-LY RE-LY ROCKET-AF NA NA NA NA
Edwards et al. [34] Bayesian MTC FE/RE OR RE-LY PETRO* NA ROCKET-AF NA NA SPORTIF III
SPORTIF V
Yes†
Roskell et al. [48]‡ Frequentist/Bayeisan MTC FE/RE RR RE-LY RE-LY NA NA RE-LY SPORTIF III
SPORTIF V
Yes§
ARISTOTLE, Apixaban for Reduction of Stroke and Other Thromboembolic Events in Atrial Fibrillation; A, apixaban; D150, dabigatran 150 mg; D110, dabigatran 110 mg; FE, ﬁxed effect; HR, hazard
ratio; ITC, indirect treatment comparison; MTC, mixed treatment comparison; NA, not applicable; OR, odds ratio; R, rivaroxaban; RCT, randomized controlled trial; RE, random effects; RE-LY,
Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET-AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation; RR, relative risk; W, adjusted-dose warfarin.
* RE-LY was included in manufacturer submission (MS) and Evidence Review Group, whereas PETRO 2007 (Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in
Patients With Nonvalvular Atrial Fibrillation) was included in MS only.
† Edwards et al. [34] included ﬁxed low-dose warfarin, aspirin, and placebo.
‡ Roskell et al. [48] indicated that RCTs were rated with a Jadad score of at least 3.
§ Roskell et al. [48] included ﬁxed low-dose warfarin, idraparinux, indobufeen, triﬂusal, aspirin, placebo/control, aspirin þ clopidogrel, warfarin ﬁxed low-dose þ apirin, and adjusted low-dose
warfarin þ aspirin.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 3 4 – 2 4 9 241provide more justiﬁcation for the model choice. For example, Wells
et al. [31] indicated that there was insufﬁcient data for the random
effects model without risking an “unintentionally large degree of
inﬂuence on any inference” and acknowledged that the results of
the ﬁxed effects model did not include the full variability in the
data. In general, the NMA results did not account for between-
study heterogeneity, because only one RCT per comparison was
available, which arguably reﬂects a limitation of the data, but
should be considered for the interpretation of the results.
Relative effect measures
There was some variation in the treatment effect measures used
across the synthesis studies, although odds ratios (ORs) and
hazard ratios were most commonly reported. It should be noted
that ORs are preferred over relative risks because they are sym-
metrical around the line of unity. There was also variation in how
some synthesis studies labeled the measures extracted from the
individual RCTs, although all three pivotal studies used a Cox
proportional hazards model.
Type of population (ITT vs. SOT)
The type of population and observation period included in the
synthesis studies by outcome was assessed where reported in
terms of ITT or SOT (see Appendix Table 3 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.012).
Four synthesis studies used an ITT population where possible
but combined different populations for at least one outcome
[31,44,47,49], whereas others seemed to (incorrectly) suggest that
only ITT was used [43,46,50]. With the exception of Kansal et al.
[45], who assessed both ITT and SOT populations separately (on
the basis of individual patient data [IPD] from RE-LY), most
studies combined different populations for some outcomes,
which reﬂects a limitation.
Reporting Quality and Transparency of Synthesis Studies
Reporting quality of the methodology of an NMA is important in
order for decision makers to critically appraise results. In most
cases, methods were reported in a sufﬁcient level of detail,
including individual study results, with some exceptions [34,36].
A graphical representation of the evidence network, however, was
presented only in select cases [31,34,44,47,48]. Generally, the key
characteristics of the RCTs were reported (except for the Evidence
Review Group report), although the type of information presented
varied. All possible treatment contrasts for the relative treatment
effects were presented, except for non-NOAC treatments [34,48].
Treatment rankings were reported only by Wells et al. [31],
although Edwards et al. [34] also used a Bayesian framework. To
facilitate the replication of ﬁndings, a more detailed description of
methods to create the data set is suggested.
Identiﬁcation of Potential Treatment Effect Modiﬁers
The importance of the similarity (or consistency) assumption
underlying an NMAwas directly addressed by the synthesis studies
either in the Methods section or in the Discussion section. It was
rare, however, that a clear list of potential treatment effect
modiﬁers was reported before reviewing study results. The process
used to identify treatment effect modiﬁers is summarized in
Appendix Table 4 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2014.10.012; however, only four synthesis
studies clearly identiﬁed differences as treatment effect modiﬁers
in the Methods section [31,36,43,45]. One synthesis study included
subgroup data for one trial, implying that the characteristic was an
effect modiﬁer [49]. Overall, the synthesis studies were generally
limited by (the reporting of) the process for identifying potential
treatment effect modiﬁers. There is a risk that deciding whichcovariates are effect modiﬁers on the basis of observed patterns in
the results across trials can lead to false conclusions regarding the
sources of inconsistency and may bias indirect comparisons [59,60].
Although most studies did not clearly identify potential treat-
ment effect modiﬁers in the Methods section, all studies identi-
ﬁed imbalances in study or patient characteristics across the
RCTs generally on the basis of a qualitative comparison in the
Results section, with select studies using a quantitative compar-
ison [44,46,47]. Differences that informed decisions regarding the
analyses tended to be reported in the Methods section (i.e.,
subgroup analyses, meta-regressions, or speciﬁc sensitivity anal-
yses) [36,43,45,48]. Testa et al. [50] was the only study that
identiﬁed differences only in the Discussion section, which
reﬂects a limitation of this study.Results of Synthesis Studies
Figure 2 illustrates the NMA results for the key comparisons of
interest for stroke or SE, MI, overall mortality, and CV death. The
efﬁcacy of dabigatran 110 mg was generally comparable to that of
rivaroxaban and apixaban in terms of stroke or SE, whereas
dabigatran 150 mg often resulted in a more favorable (non-
signiﬁcant) point estimate. Similar results were observed for
overall mortality and CV death, with select analyses favoring
dabigatran. In terms of MI, however, the efﬁcacy of both dabiga-
tran doses was unfavorable in comparison to that of rivaroxaban
and apixaban, although the treatments were often considered
comparable because of the uncertainty in the estimates.
Results from the synthesis studies for major and intracranial
hemorrhage safety end points are summarized in Figure 3.
Dabigatran 110 mg reduced the risk of a major hemorrhage in
comparison to rivaroxaban, particularly in the study by Haren-
berg et al. [44], and resulted in a comparable risk of major
hemorrhage to apixaban. Dabigatran 150 mg was considered
comparable to rivaroxaban regarding major hemorrhage despite
slightly lower point estimates, whereas in comparison to apix-
aban, dabigatran 150 mg generally resulted in higher risk. In
terms of intracranial hemorrhages, dabigatran 110 mg was
associated with a lower risk than was rivaroxaban (except among
patients with no previous stroke), and a comparable risk to
apixaban, with point estimates favoring dabigatran 110 mg. Point
estimates for dabigatran 150 mg were favorable in comparison to
those for rivaroxaban (although only Kansal et al. [45] suggested
that dabigatran 150 mg is safer than rivaroxaban) and compara-
ble to those for apixaban.Impact of Potential Treatment Effect Modiﬁers
If there is an imbalance in the distribution of effect modiﬁers
across the different types of direct comparisons in an NMA, the
corresponding indirect comparison will be biased [28]. Therefore,
it is important to assess the inﬂuence of potential treatment
effect modiﬁers to better assess the validity of the NMA results.
Differences across the trials in terms of the mean TTR in the
warfarin arm were often identiﬁed as potential treatment effect
modiﬁers [31,34,41,43–45,47] as were differences in CHADS2 score
(except for Testa et al. [50]) or baseline risk of events related to
primary or secondary prevention (i.e., history of stroke or SE) [45–
47,49]. Several synthesis studies emphasized differences in the
type of population analyzed (i.e., ITT or SOT). Table 3 summarizes
differences in the three pivotal RCTs in terms of these key
differences (Appendix Table 5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2014.10.012 summarizes the
base case and sensitivity analyses performed), which are dis-
cussed in the following sections.
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Fig. 2 – Results of network meta-analysis: Treatment estimates for efﬁcacy end points. 1 %o prev, primary prevention; 2 %o prev,
secondary prevention; CHADS2, C ¼ congestive heart failure, H ¼ hypertension, A ¼ older than age 75 years, D ¼ diabetes
mellitus, S2 ¼ prior stroke or history of transient ischemic attack; HR, hazard ratio; ITT, intention to treat; OR, odds ratio; RR,
relative risk; SOT, safety on treatment; TTR, time spent in therapeutic range.
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On the basis of TTR subgroup results from individual RCTs, Mantha
and Ansell [47] concluded that more patients with a subtherapeutic
international normalized ratio in the warfarin group of ROCKET-AF
would increase the apparent efﬁcacy of rivaroxaban versus dabiga-
tran and apixaban. Several synthesis studies acknowledged differ-
ences in TTR as a limitation that could not be explored [36,44,46,49].
Wells et al. [31] performed subgroup analyses for patients with a
TTR of less than 66% and a TTR of 66% or more where possible,
which indicated that NOACs may be less favorable for patients with
a TTR of 66% or more (Fig. 4). Also, Kansal et al. [45] performed a
comparison of dabigatran versus rivaroxaban in which ROCKET-AF
TTR was adjusted to match the RE-LY population on the basis of IPD
from RE-LY. A change of 10% in the TTR in the warfarin arm resulted
in ORs ranging from 1.051 to 1.354 across the outcomes. This
adjusted analysis illustrated some changes in the point estimates
for dabigatran versus rivaroxaban (Fig. 5), particularly in terms of
stroke or SE. The validity of this analysis depends on whether the
relationship between TTR and the risk of events in the warfarin arm
based on the RE-LY study holds true for the ROCKET-AF population,
which included patients with lower mean TTR. Because TTR is a
postrandomization variable in only the warfarin arm, there is an
increased risk that differences in TTR may introduce bias. Therefore,
synthesis studies that accounted for differences in TTR can be
considered most valid, whereas those that did not acknowledge this
limitation may be overstated.CHADS2 or baseline risk of events—Primary versus secondary
prevention
Some synthesis studies argued that because there were no
signiﬁcant interactions between treatment and CHADS2 score
(or history of embolic events) for stroke or SE in the individual
RCTs, the efﬁcacy of rivaroxaban versus warfarin may not vary
markedly across strata of CHADS2 score despite observed
differences [47]. For example, although the risk of clinical
events was higher with increasing CHADS2 scores in the RE-
LY trial, subgroups suggest that dabigatran had a consistent
beneﬁt over warfarin across CHADS2 strata [43]. Therefore, the
Evidence Review Group considered that it is likely that the
relative treatment effect is consistent across patient popula-
tions at different risk levels. Others acknowledged these differ-
ences as a limitation [44,46], whereas studies by Wells et al. [31]
(Fig. 6), Schneeweiss et al. [49] (Fig. 7), and Rasmussen et al. [36]
(Fig. 8) compared the different subgroups. Results suggest that
relative treatment effects are somewhat inﬂuenced by differ-
ences in CHADS2 score or the risk of stroke or SE at baseline,
which suggest that synthesis studies that did not account for
these differences should be interpreted with some caution.
Although subgroup analysis are limited by the amount of
information available regarding the characteristics of the sub-
groups and the small numbers of patients [31,49], they seem to
provide the most robust method to explore these differences in
the absence of IPD. A meta-regression based on study-level
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Fig. 3 – Results of network meta-analysis: Treatment estimates for safety end points. 1 %o prev, secondary prevention; 2 %o prev,
secondary prevention; CHADS2, C ¼ congestive heart failure, H ¼ hypertension, A ¼ older than age 75 years, D ¼ diabetes
mellitus, S2 ¼ prior stroke or history of transient ischemic attack; HR, hazard ratio; ITT, intention to treat; OR, odds ratio; RR,
relative risk; SOT, safety on treatment; TTR, time spent in therapeutic range.
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effect modiﬁers can only be considered as exploratory and
should be interpreted with caution given the number of data
points available.ITT population
Although per-protocol and as-treated analyses are appropriate
for noninferiority study designs, they disturb the integrity of
randomization, leading to differences in deﬁnition and follow-up,
and may confound results. The importance of using an ITT
population or the limitation of mixing population was identiﬁed
by some synthesis studies [31,34,47,49]. Results from Kansal et al.
[45], however, suggest that differences in population had only a
minor impact for some outcomes based on a comparison of RE-
LY and ROCKET-AF.Conclusions of Synthesis Studies
The conclusions of most synthesis studies either recognized that
results were based on indirect evidence or identiﬁed the need for
additional research (see Appendix Table 6 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.012).
Conﬂicts of interest were reported (see Appendix Table 7 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.10.012).Discussion
The objective of this article was to systematically review and
critically appraise published NMAs evaluating the efﬁcacy or
safety of dabigatran, rivaroxaban, or apixaban for adults with
AF on the basis of the ISPOR questionnaire. Given that it is
unlikely that an RCT comparing NOACs directly will be performed
because of the high cost and low feasibility of such a trial (due to
the required size) [42,47], it is important to assess whether the
synthesis studies provide an adequate basis for decision making.
This study provides an example of how the ISPOR NMA ques-
tionnaire can be used to critically analyze synthesis studies for
decision makers. The focus of the present article was on the
critical appraisal of NMA rather than the systematic literature
review, given that the ISPOR questionnaire aligns with accepted
guidelines (i.e., Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement).
The validity of the NMA ﬁndings depends on the quality of the
RCTs. The included synthesis studies compared the alternative
NOACs most often based on large pivotal phase III RCTs for each
NOAC versus adjusted-dose warfarin (RE-LY, ROCKET-AF, and
ARISTOTLE). The risk of bias, however, was rarely assessed
within the synthesis studies, in line with ﬁndings from a recent
NMA review on reporting quality [26]. Where reported, the RCTs
were assessed to be of sufﬁcient quality, although RE-LY was
sometimes downrated because patients were not blinded
(although outcome assessors were blinded). This may reﬂect a
Table 3 – Distribution and mean CHADS2 score.
Study Treatment Mean time
in TTR
(target INR
of 2–3)*
CHADS2
score 0–1
(%)
CHADS2
score 2
(%)
CHADS2
score 3–
6 (%)
CHADS2
score
mean
Analysis
population†
RE-LY Dabigatran 110 mg NA 32.6 24.7 32.7 2.13 ITT for all
outcomesDabigatran 150 mg NA 32.2 35.2 32.6
Warfarin 64% 30.9 37.0 32.1
ARISTOTLE Apixaban NA 34.0 35.8 30.2 2.10 ITT for efﬁcacy
outcomes and
SOT for safety
outcomes
Warfarin 62% 34.0 35.8 30.2
ROCKET-AF Rivaroxaban NA 0.0 13.0 87.0 3.48‡ ITT for primary
outcome and
SOT for other
outcomes
Warfarin 55% 0.0 13.0 86.9
CHADS2, C ¼ congestive heart failure, H ¼ hypertension, A ¼ older than age 75 years, D ¼ diabetes mellitus, S2 ¼ prior stroke or history of
transient ischemic attack; INR, international normalized ratio; ITT, intention to treat; SOT, safety on treatment; TTR, time spent in
therapeutic range.
* In ROCKET-AF, TTR included time on and off the drug (on treatment safety population), whereas in ARISTOTLE and RE-LY, only time on the
study drugs was included in this statistic [31].
† ITT in RE-LY and ARISTOTLE as all patients randomized; ITT in RE-LY and ITT in ROCK-AF deﬁned as all randomized patients, except 93 from
a Good Clinical Practice-violating site; SOT deﬁned in ROCKET-AF and ARISTOTLE as individuals who received at least one dose of a study
drug and were followed for events up to 2 days after discontinuation [47].
‡ The proportion of patients who had not had a previous ischemic stroke, transient ischemic attack, or systemic embolism and who had no
more than two risk factors was limited to 10% of the cohort for each region.
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warfarin may also be associated with some limitations [61,62].
Overall, the quality of the trials does not appear to be a major
source of bias.
Most of the analyses were based on the same evidence base
and used similar methods for the analysis. Overall, the NMA
methods were valid and most importantly acknowledged within-
trial randomization and therefore yielded similar results. The
NMAs were generally limited by the number of data points
available based on the publications. For example, given the
available data, ﬁxed effects models were used; therefore, results
do not incorporate between-study heterogeneity. Although the
methods were generally well reported, the use of ITT or SOT
populations from individual RCTs was not always clear in theig. 4 – Overview of results from Wells et al. [31] for full populatio
nd TTR 66% or more for NOACs versus warfarin. NOACs, new osynthesis studies and in some cases these populations were
mixed in the analysis, which again reﬂects a limitation of the
information that has been reported publicly for speciﬁc outcomes
in many cases. Given the small number of events overall in this
disease area, differences in terms of population may have a more
substantial impact in other disease areas. Inconsistencies regard-
ing the use of ORs, relative risks, or hazard ratios in the synthesis
studies were identiﬁed, although this may be related to differ-
ences in labeling or due to the simplicity of the model used (i.e.,
Bucher) and the available information reported. The synthesis
studies evaluated stroke or SE on the basis of constant hazard
ratios, rather than the cumulative event probabilities reported;
therefore, a multidimensional treatment effect that does not rely
on the Cox proportional hazard assumption may be of interest forn, subgroup time in therapeutic range (TTR) less than 66%,
ral anticoagulants.
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trial data could be achieved. Despite these limitations, the
methods for the base case analyses were generally satisfactory
given the reported results available, although more sophisticated
methods using a Bayesian framework may be preferable for
decision making.
It should also be noted that many of the synthesis studies did
not present their results in terms of an absolute or expected
overall effect per treatment. It is possible to apply the relative
effects to an absolute baseline (warfarin) effect to translate the
results into alternative measures that may help clinicians better
understand results of the NMA for a speciﬁc population. Fur-
thermore, for CV diseases, results of individual trials are often
presented in terms of “number needed to treat,” which may help
provide a more intuitive result for clinicians. If this approach to
communicate NMA results is used, it should be noted that a clear
description of the target population of interest, as well as the data
and model used to inform the annual risk of stroke, is required
because the composition of risk factors will affect the interpre-Fig. 6 – Overview of results from Wells et al. [31] for full popula
score of 2 or more for NOACs versus warfarin. CHADS2, C ¼ con
years, D ¼ diabetes mellitus, S2 ¼ prior stroke or history of tratation of the results. Presenting this information may help
illustrate how individual decision makers can apply NMA results
to a speciﬁc population of interest.
A limitation of the present review is that results of the individual
RCTs were not extracted. Therefore, it was not possible to compare
the results as presented by each analysis to the reported RCTs to
detect potential errors or differences across the synthesis studies. In
addition, as with any systematic review, not all recent NMAs
published were captured by the search [66,67]. Moreover, protocols
are now available for several reviews and/or synthesis studies that
are planned or ongoing [68–70], which reinforces the number of new
synthesis studies in this area and therefore the importance of
critically analyzing this type of evidence systematically.
Although it is reassuring that results of the NMAs were
generally consistent, it is important to consider that the validity
of the NMA results depends on the extent of any violations in the
similarity and consistency assumptions across studies [71].
Because the randomization in an NMA holds only within the
individual trials (and not across trials), it is necessary to assesstion, subgroup with CHADS2 score of less than 2, and CHAD2
gestive heart failure, H ¼ hypertension, A ¼ older than age 75
nsient ischemic attack; NOACs, new oral anticoagulants.
Fig. 7 – Overview of results from Schneeweiss et al. [49] for full population and subgroup CHADS2 score of 3 or more for
dabigatran 150 mg versus apixaban. CHADS2, C ¼ congestive heart failure, H ¼ hypertension, A ¼ older than age 75 years, D ¼
diabetes mellitus, S2 ¼ prior stroke or history of transient ischemic attack.
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characteristics of the RCTs in the different direct comparisons
that act as treatment effect modiﬁers. In contrast to a previous
review [26], the similarity and consistency assumptions were
frequently mentioned. The process to identify treatment effect
modiﬁers, however, was not well described, which reﬂects an
important process that requires further research. Nonetheless,
several differences across the RCTs emerged as potential treat-
ment effect modiﬁers, including mean TTR in the warfarin arm,
primary or secondary prevention (i.e., mean CHADS2 score or risk
of stroke or SE), and the type of population (i.e., ITT or SOT),
which is consistent with previous reviews [42,72].
In many cases, a meta-regression may minimize confounding
bias by adjusting for inconsistencies in the evidence base. A trial-
level covariate of interest as a possible source of heterogeneity (or
inconsistency) is the “baseline risk” or the underlying risk of the
disease or event [73]. Baseline risk reﬂects the burden of disease
in a study population and deﬁnes the average risk of a patient to
experience the outcome of interest if the patient has not been
treated [74]. Baseline risk may be a proxy for the number of (un)
measured patient-level characteristics that collectively inﬂuence
a patient’s response to treatment [73,75]. Therefore, this type of
adjustment in the common comparator, such as warfarin, may
improve the similarity of the trials by adjusting for differences,ig. 8 – Overview of results from Rasmussen et al. [36] for seconda
revious stroke).for example, in terms of primary or secondary prevention (related
to factors such as CHADS2 scores). For the present research
question, however, adjusting for any covariates is not expected
to provide reasonable estimates regarding the relationship
between the treatments and the potential treatment effect
modiﬁers given the limited number of data points available from
published studies. Therefore, alternative methods are required to
explore differences in potential treatment effect modiﬁers.
In the absence of IPD for any studies, subgroups data can be
used to assess the impact of potential treatment effect modiﬁers,
as was done by Wells et al. [31] (TTR o 66% and TTR Z 66%;
CHADS2 scoreo 2 and CHADS2 scoreZ 2), Schneeweiss et al. [49]
(CHADS2 score Z 3), and Rasmussen et al. [36] (previous stroke
yes or no). Although these kinds of subgroup analyses are limited
by the amount of information available regarding the patient
characteristics of the subgroups, and have limited power, they
seem to be the best alternative method to explore these differ-
ences (assuming that IPD are not available). Results of these
analyses identiﬁed some minor differences in the point estimates
regarding the comparative effectiveness of the alternative NOACs
although they did not have a dramatic impact on results. It
should be noted, however, that restricting to subgroups, such as
patients with a CHADS2 score of 3 or more (as done by Schnee-
weiss et al. [49]), may still leave gaps in the evidence to informry prevention (previous stroke) and primary prevention (no
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 3 4 – 2 4 9 247decisions regarding the broader population, given that patients
with a CHADS2 score of 1 or more stroke risk factor are eligible for
anticoagulants [42].
If IPD are available for one of the new treatments (often by a
single manufacturer), it is possible to use these IPD to estimate
the impact of a particular characteristic on an outcome, which
can be assumed to apply to other studies. Kansal et al. [45]
performed this type of analysis for the comparison of dabigatran
versus rivaroxaban, where ROCKET-AF TTR was adjusted to
match the RE-LY population and consistent analysis populations
were used. This adjustment was based on IPD from the RE-LY trial
to estimate the effect of a change in the TTR in the warfarin arm.
Kansal et al. [45] seem to provide the most robust assessment
regarding the validity of the results for the comparison of
dabigatran to rivaroxaban. Because these results do not differ
dramatically from those of other synthesis studies, it seems that
these differences in TTR should be acknowledged but may not be
the primary driver of the efﬁcacy and safety for the NOACs.
Similarly, the sensitivity analysis performed by Kansal et al. [45]
by using either ITT or SOT populations implies that differences
due to the type of analysis population may not invalidate results
of other synthesis studies. The validity of the TTR analysis,
however, depends on whether the relationship as estimated holds
true for the ROCKET-AF population, which included patients with
a lower mean TTR. Therefore, there is still some uncertainty
regarding the impact of TTR based on this analysis, as well as for
treatments not included in the analysis (i.e., apixaban), and for
those differences not explored, such as primary or secondary
prevention (or differences in terms of CHADS2 scores).
The ISPOR questionnaire provides a useful overview of the
available evidence for clinicians and decision makers; however,
the tool does not necessarily address the limitations of the
synthesis studies in terms of answering important remaining
questions. For example, although differences in terms of primary
versus secondary prevention (or differences in baseline CHADS2
scores) were identiﬁed as a potential treatment effect modiﬁer on
the basis of results of the questionnaire, the potential importance
of this question for decision makers cannot be derived from the
application of the questionnaire. Although in many other indi-
cations primary and secondary prevention is clearly differenti-
ated on the basis of risk and treatment guidelines, stroke
prevention in AF is unique in that anticoagulant treatments
target AF as the main risk factor for a clot, and subsequently
for a stroke, regardless of the patient’s history in terms of
transient ischemic attack, SE, or a stroke. Consequently, NOACs
are relevant for both primary and secondary prevention, and
therefore the indicated labels and treatment guidelines do not
differentiate the type of prevention. Although previous stroke is a
risk factor itself, even in patients with AF, NOACs target the
underlying cause for both primary and secondary prevention
patients, and it remains unclear whether primary and secondary
prevention is a treatment effect modiﬁer. This differs in the case
of secondary prevention of stroke without AF (e.g., crytopengic
stroke), in which case NOACs are not indicated given the differ-
ence in the underlying cause.
Overall, the synthesis studies are not expected to be severely
biased because of differences identiﬁed on the basis of analyses
that have been performed to explore potential treatment effect
modiﬁers. Therefore, in terms of stroke or SE, dabigatran 150 mg
is expected to provide the most efﬁcacious NOAC, whereas in
terms of major hemorrhage, apixaban is expected to provide the
safest NOAC. Because the magnitude of differences between the
NOACs based on the NMA results is consistently small, there is
still a risk that differences across the RCTs may inﬂuence the
NMA conclusions regarding the optimal NOAC. To draw stronger
conclusions regarding the optimal NOAC, an NMA based on IPD
from all three pivotal trials is required to simultaneously adjustfor potential treatment effect modiﬁers, such as TTR and primary
or secondary prevention (i.e., CAHDS2 scores). Given that the
conclusions of the analysis may depend on the outcome of
interest, it would be necessary for all end points relevant for
decision makers to be considered simultaneously, which may be
possible using a stochastic multicriteria acceptability model [76].
This reﬂects an important area for future research, to account for
alternative efﬁcacy and safety outcomes as well as individual
preferences, which may depend on several attributes such as
baseline risk, age, or sex. These conclusions highlight the need
for improved access to IPD across RCTs developed by different
manufacturers, especially in a disease area in which an RCT
directly comparing all NOACs is very unlikely to be performed.Acknowledgment
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